NRXS (Neuraxis) Accounts Payable & Accrued Expense : $1.91 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Accounts Payable & Accrued Expense?

Neuraxis's quarterly accounts payable & accrued expense declined from Sep. 2024 ($2.13 Mil) to Dec. 2024 ($0.91 Mil) but then increased from Dec. 2024 ($0.91 Mil) to Mar. 2025 ($1.91 Mil).

Neuraxis's annual accounts payable & accrued expense declined from Dec. 2022 ($1.89 Mil) to Dec. 2023 ($1.27 Mil) and declined from Dec. 2023 ($1.27 Mil) to Dec. 2024 ($0.91 Mil).

Neuraxis Accounts Payable & Accrued Expense Historical Data

The historical data trend for Neuraxis's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Accounts Payable & Accrued Expense Chart

Neuraxis Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

0.83

1.03

1.89

1.27

0.91

Neuraxis Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial										2.05	2.43	2.13	0.91	1.91

Neuraxis Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Neuraxis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

11611 N. Meridian Street, Suite 330, Carmel, IN, USA, 46032

Website

http://www.neuraxis.com

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Executives

Masimo Corp	10 percent owner	52 DISCOVERY, IRVINE CA 92618
John G Seale	officer: CHIEF FINANCIAL OFFICER	10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico	director, officer: CEO, DIRECTOR	11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown	director, officer: DIRECTOR OF INNOVATION	829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence	officer: CHIEF OPERATING OFFICER	10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico	officer: CHIEF REGULATORY OFFICER	829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson	officer: DIR.OF DESIGN & ENGINEERING	829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins	director	10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser	director	220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs	director	324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda	officer: Chief Medical Officer, SVP	829 S. ADAMS STREET, VERSAILLES IN 47042